DRIVEN

We have initiated a Phase 1 SAD/MAD clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of THB335 in healthy volunteers, followed by a Phase 2 trial in chronic spontaneous urticaria, with planned expansion into additional mast cell-mediated disorders. Clinical results from the Phase 1 study are expected to be reported during the first quarter of 2025.